俯卧位光子计数CT碘图鉴别乳腺肿块的前瞻性研究
前瞻性单中心研究纳入78例参与者共134个乳腺肿块(106恶性、28良性),评估俯卧位无压迫光子计数CT碘图、65 keV单能后对比图像及虚拟平扫对肿块的显示与鉴别能力。乳腺癌中位碘浓度最高(2.6 mg/mL),显著高于导管原位癌(1.7 mg/mL)、纤维腺瘤(0.5 mg/mL)和囊肿(-0.1 mg/mL);乳头状瘤和淋巴结碘值与癌重叠。结论认为该方法可准确定位、定量并鉴别良恶性乳腺肿块,可能作为MRI的可及性辅助手段。
要点
- 乳腺癌中位碘浓度2.6 mg/mL,显著高于导管原位癌1.7 mg/mL、纤维腺瘤0.5 mg/mL和囊肿-0.1 mg/mL。
- 乳头状瘤和淋巴结碘值与乳腺癌重叠,鉴别时需注意。
- PC-CT C+的CNR高于PC-CT碘图(P<0.001),阅片者偏好碘图用于检出、C+用于形态评估。
核心结论
- 俯卧位光子计数CT碘图可准确定位、定量并鉴别良恶性乳腺肿块,无压迫体位提高定位准确性,可能作为MRI的可及性辅助手段用于分期,推荐联合使用碘图与后对比重建以获得最佳评估。
研究设计与样本
- 前瞻性单中心研究(2021年12月至2023年8月),纳入活检证实的乳腺癌患者,行俯卧位无压迫乳腺定位的胸腹部PC-CT、乳腺MRI和断层合成摄影;重建包括PC-CT碘图、65 keV PC-CT C+和PC-CT VNC;最终纳入78例参与者(平均年龄55岁±15 SD,77名女性)共134个乳腺肿块(106恶性、28良性)。
诊断标准与关键数值
- 乳腺癌中位碘浓度2.6 mg/mL(IQR 2.0–3.3),显著高于DCIS 1.7 mg/mL、纤维腺瘤0.5 mg/mL和囊肿-0.1 mg/mL(均P<0.05);乳头状瘤和淋巴结碘值与癌重叠(P>0.05);PC-CT C+的CNR高于PC-CT碘图(P<0.001)。
临床应用与阅片要点
- 阅片者偏好PC-CT碘图用于病灶检出、PC-CT C+用于形态学评估;病灶定位与MRI一致,未见相关伪影;作者推荐联合使用碘图与后对比重建以获得最佳评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Photon-counting CT (PC-CT) offers higher spatial resolution and enables iodine quantification compared with conventional CT. Its potential role in breast imaging is currently under evaluation.
PURPOSE: To assess whether prone-positioned PC-CT with iodine mapping can differentiate malignant from benign breast masses, and to evaluate the clinical utility of iodine mapping (PC-CT Iodine ), monoenergetic postcontrast images (PC-CT C+ ), and virtual noncontrast reconstructions (PC-CT VNC ) for lesion conspicuity, image quality, anatomic correlation with MRI, and reader's preference.
MATERIALS AND METHODS: This prospective single-center study (December 2021 to August 2023) included patients with biopsy-proven breast cancer who underwent thoracoabdominal PC-CT in prone, compression-free breast positioning, breast MRI, and tomosynthesis during staging. Reconstructions included PC-CT Iodine , PC-CT C+ with 65 kiloelectronvolts (keV), and PC-CT VNC . Quantitative analysis included iodine concentrations and contrast-to-noise ratio (CNR), each with additional subtype analysis; qualitative ratings included lesion conspicuity, noise, artifacts, lesion localization, and reader preferences. Statistical analysis included Kruskal-Wallis, Friedman and Wilcoxon signed-rank tests, and Cohen kappa.
RESULTS: Among 90 potentially eligible participants, 78 participants (mean age, 55 y ± 15 SD, 77 women) with 134 breast masses (106 malignant, 28 benign) were included. Benign masses differed from malignant lesions ( P < 0.001). Breast cancers showed the highest median iodine concentration [2.6 mg/mL (IQR, 2.0 to 3.3)], significantly higher than DCIS (1.7 mg/mL), fibroadenomas (0.5 mg/mL), and cysts (-0.1 mg/mL; all P < 0.05). Iodine values for papillomas and lymph nodes overlapped with cancers ( P > 0.05). CNR was higher for PC-CT C+ than PC-CT Iodine ( P < 0.001). Readers preferred PC-CT Iodine for detection and PC-CT C+ for morphologic assessment. Lesion localization matched MRI, and no relevant artifacts were observed.
CONCLUSION: Prone PC-CT with iodine mapping enables accurate lesion localization, quantification, and differentiation between malignant and benign breast masses. Compression-free breast positioning enhances localization accuracy. The method may serve as an accessible adjunct to MRI in staging, with complementary use of iodine and postcontrast reconstructions recommended for optimal assessment.
引用
- Wilpert C, Pichotka MP, Molina-Fuentes MF, et al. Prone Photon-counting Computed Tomography With Iodine Mapping for Differentiating Breast Masses: A Prospective Study. Invest Radiol. 2026. PMID: 41437879. doi:10.1097/RLI.0000000000001263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。